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Visual hallucinations (VH) are commonly found in the course of synucleinopathies like 
Parkinson's disease and dementia with Lewy bodies. The incidence of VH in these 
conditions is so high that the absence of VH in the course of the disease should raise 
questions about the diagnosis. VH may take the form of early and simple phenomena 
or appear with late and complex presentations that include hallucinatory production and 
delusions. VH are an unmet treatment need. The review analyzes the past and recent 
hypotheses that are related to the underlying mechanisms of VH and then discusses their 
pharmacological modulation. Recent models for VH have been centered on the role played 
by the decoupling of the default mode network (DMN) when is released from the control of 
the fronto-parietal and salience networks. According to the proposed model, the process 
results in the perception of priors that are stored in the unconscious memory and the 
uncontrolled emergence of intrinsic narrative produced by the DMN. This DMN activity is 
triggered by the altered functioning of the thalamus and involves the dysregulated activity 
of the brain neurotransmitters. Historically, dopamine has been indicated as a major driver 
for the production of VH in synucleinopathies. In that context, nigrostriatal dysfunctions 
have been associated with the VH onset. The efficacy of antipsychotic compounds in 
VH treatment has further supported the notion of major involvement of dopamine in the 
production of the hallucinatory phenomena. However, more recent studies and growing 
evidence are also pointing toward an important role played by serotonergic and cholinergic 
dysfunctions. In that respect, in vivo and post-mortem studies have now proved that 
serotonergic impairment is often an early event in synucleinopathies. The prominent 
cholinergic impairment in DLB is also well established. Finally, glutamatergic and gamma 
aminobutyric acid (GABA)ergic modulations and changes in the overall balance between 
excitatory and inhibitory signaling are also contributing factors. The review provides 
an extensive overview of the pharmacology of VH and offers an up to date analysis of 
treatment options.
Keywords: visual hallucination, dementia with Lewy bodies, Parkinson's disease, synucleinopathy, default 
mode network
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iNTRODUCTiON
The focus of the review concerns visual hallucinations (VH), a 
prominent feature of Parkinson's disease (PD) and dementia with 
Lewy bodies (DLB). The review is structured as a short overview 
of the clinical presentations, a detailed analysis of the mechanisms, 
neurotransmitters, and neural networks that are involved in the 
process (Table 1). Finally, the review dissects drugs that are related 
to the induction and resolution of VH (Table 2).
Clinical Setting
VH and rare hallucinations in other modalities are the hallmarks 
of synucleinopathies like PD, Parkinson's disease with dementia 
(PDD), and DLB. Explorative or consensus studies (Onofrj et al., 
2002; Diederich et al., 2005; Goetz et al., 2011) have analyzed 
the time of appearance, prevalence, and correlation of VH with 
ongoing cognitive decline (Barnes et al., 2003; Ramirez-Ruiz et al., 
2006; Ramirez-Ruiz et al., 2007; Barnes and Boubert, 2008) and 
indicated that VH are associated with and predict the presence 
of α-synuclein (i.e., Lewy bodies) deposits (Harding et al., 2002; 
Williams and Lees, 2005; Halliday et al., 2011). The phenomenon 
is so common in the disease progression that a brain bank-
related study demonstrated that if no history of VH is found in 
the PD course, the diagnosis should be challenged (Williams 
and Lees, 2005). VH are also a core criterion for the diagnosis 
of DLB (McKeith et al., 2017). Upon the clinical course of PD, 
VH can appear as simple or complex phenomena. The original 
dichotomy between early-simple and late-complex presentations 
of VH (Fénelon et al., 2000; Barnes and David, 2001) has been 
nowadays discarded by evidence showing that the occurrence 
of VH invariably bears an unfavorable prognostic outcome, 
independently of the time of appearance (Goetz et al., 2006). It is 
nevertheless true that simple VH occur in the early stage of the 
disease. Simple VH are usually described as altered perceptions of 
blurred moving images occurring in/or outside of the visual field 
(extracampine hallucinations) (Chan and Rossor, 2002; Diederich 
et al., 2005). VH can also take the form of simple distortions of 
images often characterized by the association with humanized 
traits (eidol-idol) of elements that are present in the visual field 
(Ey, 1973). The phenomenon is commonly and more properly 
described as "illusions" or "pareidolia," events that are the result 
of distorted perceptions (Uchiyama et al., 2012). VH occurring 
TABLe 1 | Neurotransmitters acting on visual hallucinations (VH) onset and resolution. 
Serotonergic system
Seven subfamilies of receptors (from 5HT1 to 5HT7)
Receptor Mechanism of action Sites of action effects on VH
5HT1A Antagonism Raphe nuclei of medulla oblongata, amygdala, and hippocampus Induction
5HT2A Agonism
Antagonism
Prefrontal cortex, anterior and posterior cingulate cortex Induction
Inhibition
5HT2C Agonism Prefrontal cortex, anterior cingulate cortex, and ventral tegmental area Induction
5HT3 Antagonism
Agonism
Area postrema, nucleus tractus solitarius, amygdala, and dorsal raphe nucleus Inhibition
Induction
SERT Inhibition Caudate nucleus, putamen, posterior cingulate cortex Inhibition
Dopaminergic system
Five subtypes of receptors (D1R to D5R)
Receptor Mechanism of action Sites of action effects on VH
D2-like (D2R, D3R) Antagonism Striatum, external globus pallidus, nucleus accumbens, amygdala, cerebral cortex, 




Two families of receptors (muscarinic and nicotinic receptors)
Receptor/substrate Mechanism of action Sites of action effects on VH
mAchR Antagonism Striatum, thalamus, ventral tegmental area, hippocampus, and substantia nigra 
(pedunculopontine network and basal forebrain network)
Induction
AchE Inhibition CNS Inhibition
Glutamatergic system
Two types of receptors: ionotropic glutamate receptors (AMPA, kainate, and NMDA) and metabotropic glutamate receptors (mGluR 1–8 receptors)
Receptor Mechanism of action Sites of action effects on VH
NMDAR Antagonism Ventral subiculum Induction
Opioid system
Three types of receptors: KOR, MOR, DOR
Receptor Mechanism of action Sites of action effects on VH
KOR Agonism Hypothalamus, periaqueductal gray, and claustrum Induction
MOR Agonism Cortex, hypothalamus, periaqueductal gray, striosomes, rostral ventromedial medulla Induction
The table outlines the main sites of action, at molecular and anatomical level, of the neural networks involved in VH.
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in the early course of DLB and cognitively-preserved PD patients 
are perceived as extraneous to reality by the hallucinating subject 
and they suddenly appear in the form of complex images, animals, 
or miniature figures (Onofrj et al., 2013) that generally disappear 
when the patient, employing a coping strategy, refocuses his/her 
attention (Diederich et al., 2009). With the disease progression 
and the appearance of cognitive decline, early VH that are initially 
associated with preserved insight are then replaced by complex 
VH (Fénelon, 2006). At later stages, DLB patients may be clinically 
indistinguishable from PDD patients who exhibit VH along 
with prominent cognitive impairment. Thus, clear quantitative 
and/or qualitative distinctions between DLB patients and PDD 
patients cannot be made as complex VH are the most common 
manifestation of both conditions. Complex VH are characterized by 
the loss of insight and the presence of a complex narrative structure 
(Onofrj et al., 2001; Fénelon, 2006). In complex VH, hallucinating 
images do interact and move across the visual field with kinetic 
properties, thereby generating enriched scenarios (i.e., fighting 
demons, marching warriors, multi-colored funerals, molesting 
presences) (Fénelon, 2006; Onofrj et al., 2006; Diederich et al., 2009; 
Onofrj et al., 2013). These complex VH are named paraphrenic 
hallucinations (Ey, 1973). Complex VH may exhibit different 
duration and onset time. In the early stages, they typically represent 
a transient phenomenon often prone to spontaneous remission. 
However, VH may also occur as a continuous hallucinatory state 
akin to a "crepuscular status" that lasts for days or until treatment 
is started. Although there is no substantial evidence supporting the 
notion of a progression from simple to complex VH occurring in 
the same PD patient, the appearance of VH almost always predicts, 
since early stages, within a definite and foreseeable time frame, the 
incoming occurrence of cognitive decline (Onofrj et al., 2007).
The present review also focuses on the biochemical basis of VH 
in hallucinatory phenomena triggered by drugs or neurological 
conditions. Drug-induced hallucinations are typically driven by 
the activation of the serotonergic system (as in the case of LSD or 
psilocybin) and involve sensorial modalities in addition to the visual 
one (Geyer and Vollenweider, 2008). Time and space dysperceptions, 
ego-dissolution, depersonalization, derealization, and cenesthetic 
hallucinations are quite common upon the consumption of 
psychedelic compounds (Geyer and Vollenweider, 2008; Carhart-
Harris et al., 2010). However, drug-induced hallucinations may 
exhibit different presentations when occurring in the context of 
underlying neurodegenerative disorders. This is especially true in 
the case of hallucinatory-prone diseases like synucleinopathies. In 
addition, non-psychedelic drugs can bring on or exacerbate VH 
in PD or DLB patients. The reason for these phenomena relies on 
the overall impairment of multiple neurotransmitters and neural 
networks promoted by the degenerative processes (Carhart-Harris 
et al., 2012; Muthukumaraswamy et al., 2013; Carhart-Harris et al., 
2016). The complexity of these neurochemical and/or network 
interactions are the focus of ongoing in-depth investigations aimed 
at identifying the distinct contribution of each neurotransmitter and 
neural circuitry to the production of the hallucinatory phenomena 
in different clinical settings.
The Theoretical Framework: Thalamic-
Driven Decoupling of the Default  
Mode Network
Early studies, at the beginning of the levodopa era, have proposed 
that the presence of VH in PD patients was the results of 
pharmacological treatment (Moskovitz et al., 1978; Poewe, 2003). 
The hypothesis was eventually disproved by studies showing no 
direct correlations with the levodopa administration. VH have 
also been linked to the presence of neuronal hyperexcitability and 
increased spontaneous activity occurring within the higher visual 
cortex; phenomena once considered to be triggered by an ongoing 
condition of chronic functional deafferentation (Onofrj et al., 
1986; Ghilardi et al., 1988; Ffytche, 2007). The model implied the 
presence of dopamine-dependent visual dysfunctions but has been 
TABLe 2 | The table encompasses common causes of drug-induced visual 



















































The lower part of the table shows instead suitable therapeutic options for VH in 
synucleinopathies.
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disproved by three lines of evidence as 1) in non-hallucinating 
PD subjects, visual dysfunctions are corrected by dopaminergic 
drugs while PD-related VH are actually triggered by the same 
compounds; 2) there is no increased incidence of VH in PD 
patients who are also affected by eye diseases; 3) the hallucinations 
found in PD and DLB patients can exhibit multimodal features.
A more recent model for VH has considered the phenomenon 
as the result of a thalamic-driven derangement of the activity of 
top-down attentional processing of visual stimuli (Figure 1). The 
model posits that alterations of the network balance affect the brain 
computational processes involved in predictive coding (Friston, 
2010; Sterzer et al., 2018). According to the model, VH arise when 
the overall prevalence of priors (i.e., the inner prior knowledge 
of likely candidates that match a given sensory input) over 
perceptions generates new percepts that are not based on matching 
stimuli (Clark, 2013). The process depends on the dysregulated 
activity of the DMN. The model further posits a sequence of events 
by which VH are generated when the uncontrolled activity of the 
DMN escapes from the modulatory activity exerted by the task-
positive networks [TPNs, a set of networks like the dorsal attention 
network (DAN) and ventral attention network (VAN) that 
respond with increased activation to cognition-demanding tasks]. 
Thus, upon the TCD-like thalamic activity and the uncoupling 
from TPNs, the DMN enters in an unstable, entropic, state that 
unleashes the production of oneiric, dissociative, or altered state 
of consciousness, and ultimately VH (Muthukumaraswamy et al., 
2013; Carhart-Harris et al., 2014; Carhart-Harris et al., 2016).
The Thalamic Driver
Based on a growing body of evidences, it has also been proposed that 
the thalamus is the driver for these unbalanced network activities 
as this subcortical hub is critical to combine thalamic sensory 
filtering as well as the generation of thalamic rhythms associated 
with the thalamocortical dysrhythmia (TCD) complex (Llinàs 
et  al., 1999 Vanneste et al., 2018). Historically, the thalamus has 
been viewed as a relay station for the transmission of sensory and 
motor information to the cortex. More recent evidence indicates 
that the thalamus is a key hub of the DAN, VAN, and DMN. This 
filtering activity, particularly in the case of somatic sensations and 
visual stimuli, is carried out by the first-order thalamic nuclei like 
the ventral posterior nucleus (VPN) and the lateral geniculate 
nucleus (LGN) (Ward, 2013). The thalamus exerts critical filtering 
within cortical-striatal-thalamo-cortical loops and the prefrontal 
cortex (Geyer and Vollenweider, 2008). The striatum inhibits 
the thalamic filtering and the dopamine- and serotonin-driven 
thalamic activation promotes the sensory overload to the cortex that 
generates cognitive disruptions, ego dissolution, and altered states 
of consciousness (Vollenweider, 2001a; Sherman, 2016; Halassa and 
Kastner, 2017). Through inputs from the associative (mediodorsal 
and intralaminar) and posterior (ventral-posterior and pulvinar) 
nuclei, the thalamus controls critical nodes of the DMN [i.e., the 
medial prefrontal cortex (mPFC) and posterior cingulate cortex 
(PCC)]. The thalamoreticular nucleus (TRN), a shell of GABA-
releasing neurons surrounding the thalamic circuits (Pinault, 2004; 
Benarroch, 2013), receives excitatory inputs from the cortex and 
the dorsal thalamus and, in turn, projects inhibitory efferent inputs 
to the high-order thalamic nuclei (Benarroch, 2013; Ward, 2013). 
Hence, TRN acts as the real pacemaker of thalamocortical loops 
(Min, 2010). TRN oscillations are a pivotal factor for the indirect 
modulation of cortical activity (in particular, layers IV, V, VI) in 
physiological and pathological conditions (Ward, 2011). TRN also 
receives cholinergic inputs from the pedunculopontine nucleus 
(PPN) and inhibitory GABAergic inputs from the globus pallidus 
(Benarroch, 2013). The PPN, a brainstem nucleus consisting of 
FiGURe 2 | Main hubs of ventral attention system (VAN), dorsal attention 
system (DAN), and default mode network (DMN).
FiGURe 1 | Top-down processing of perception. The scheme depicts the 
visual (top) and somatosensory (bottom) pathways that are involved in the 
activation of the default mode network and hippocampus. Abbreviations: V1, 
V2, V4 visual areas; ITC, inferior temporal cortex; TP, temporal pole; 3,1,2 
somatosensory areas.
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cholinergic neurons, controls the thalamocortical excitability and 
behavioral outputs. The PPN activates the thalamocortical neurons 
and promotes the high-frequency cortical oscillations (burst-firing 
mode) associated with wakefulness.
Default Mode Network Decoupling in the 
Production of Visual Hallucinations
Central to the thalamic-driven model of VH is the altered 
functioning of the DMN. The DMN is involved in multiple 
functions related to self-relevant and internally directed 
information processing (Figure 2) (Andrews-Hanna et al., 2014; 
Raichle, 2015). The DMN is deactivated upon task execution 
(Supplementary Video 1) and exhibits high levels of activity at 
rest (Raichle et al., 2001). TPNs monitor and keep in check the 
DMN activity (Fox et al., 2005). The inverse coupling between 
the DMN and TPNs is at the core of the brain metastability. 
Alterations of the metastability lead to decreased inhibition of 
the DMN that promotes the intrusion of unstable perceptions 
(Garrity et al., 2007; Jeong and Kubicki, 2010), a process facilitated 
by the down-regulation of the TPNs (Wotruba et al., 2014). A 
critical player in the production of the network unbalance is 
the PCC (Figure 3), a region belonging to the DMN (Leech and 
Sharp, 2014) that exhibits transitional patterns of connectivity 
with TPNs. The overactivation of the dorsal PCC has been 
linked to the intrusion of introspective mental activities into 
task performances (Supplementary Video 2) (Weissman et al., 
2006; Sonuga-Barke and Castellanos, 2007). The complexity of 
PCC functioning has been revealed by the experimental use of 
psychedelic drugs. These compounds alter the connectivity of the 
PCC and DMN (Muthukumaraswamy et al., 2013; Carhart-Harris 
et al., 2017) and generate psychedelic phenomena through the 
5-hydroxytryptamine (5-HT)2A-dependent disinhibition of the 
thalamus and the overactivation of the PCC (Preller et al., 2019).
We and others have proposed that VH are generated by a 
synuclein-driven combination of thalamic- and PPN- driven 
dysfunctions (Henderson et al., 2000; Rub et al., 2002; Pimlott 
et al., 2006; Janzen et al., 2012; Onofrj et al., 2019). In the model, 
PPN alterations promote the TRN activation and the inhibition 
of the first-order nuclei of the thalamus, thereby ultimately 
generating pathological, "TCD-like," theta rhythms. These theta 
rhythms affect the thalamic modulation of cortico-cortical loops 
and unleash the DMN hyperactivity. Thalamic dysfunctions 
synergistically act to alter the filtering of external and internal 
information, in a process, similar to lysergic acid diethylamide 
(LSD)-driven mechanisms, that inundate the primary cortex 
with an overload of irrelevant information (Preller et al., 2019). 
The altered functioning of the DMN and the visual pathways 
promote the incorrect inclusion of contents of visual perception 
into the autobiographical narrative (Shine et al., 2014; Franciotti 
et al., 2015; Bejr-Kasem et al., 2019). Supporting this model, PD 
or DLB patients suffering from VH exhibit increased DMN-
driven activation of the visual cortex (Shine et al., 2015) as well 
as structural alterations occurring in the DAN and VAN (Delli 
Pizzi et al., 2014; Goldman et al., 2014; Weil et al., 2016).
NeUROTRANSMiTTeRS iNVOLVeD iN 
ViSUAL HALLUCiNATiONS
The interplay of Neurotransmitters 
involved in the Physiology and Pathology 
of Visual Processing
The physiological modulation of visual processing requires a 
complex interplay among several neurotransmitters (Table  1). 
Dopaminergic, serotonergic, cholinergic, and GABAergic 
neurons are largely involved in these processes (Jacob and 
Nienborg, 2018). Second-order thalamic nuclei receive dense 
dopaminergic projections arising from pars compacta of the 
FiGURe 3 | Fludeoxyglucose F 18 (18F-FDG) positron emission tomography standard axial view transacting the posterior cingulate region obtained in a healthy 
control (A); in a patient with Lewy bodies dementia (DLB) (B); in an Alzheimer disease (AD) patient (C). Note that reduced 18F-FDG uptake, indicative of glucose 
hypometabolism and reduced synaptic activity, is present in the occipital lobes while preservation of metabolic activity is found in the posterior cingulate cortex (red 
arrow). This feature, known as the "cingulate island sign," is often seen in DLB but not AD patients.
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substantia nigra (SN), ventral tegmental nuclei, pontine nuclei, 
hypothalamus, periaqueductal gray, ventral mesencephalon, and 
parabrachial regions (Sánchez-González et al., 2005; Jacob and 
Nienborg, 2018). Several observations indicate the participation of 
serotonin (Marek et al., 2001; Barre et al., 2016) and noradrenaline 
(Morrison and Foote, 1986; Jacob and Nienborg, 2018) in the 
early and complex visual processing as well as in the behavioral 
responses (inhibition/arousal) to visual inputs. These processes are 
obtained by modulating the activity of the sensory cortices, TRN, 
and selected thalamic nuclei, as well as distinct thalamocortical 
circuitry (Jacob and Nienborg, 2018). Furthermore, cortico-
cortical glutamatergic and GABAergic projections are the main 
pathways connecting the nodes of the DAN, VAN, and DMN, 
whereas glutamatergic projections originating from high order 
thalamic nuclei reach different cortical areas and are modulated by 
GABAergic projections sprouting from the TRN.
Serotonergic System
Dysfunctions of serotonergic networks have been extensively 
described in synucleinopathies (Braak et al., 2003; Seidel et al., 
2015). According to a recent and intriguing study, the appearance 
of pathological alterations of these networks precedes the 
occurrence of dopaminergic impairment, in carriers of the A53T 
mutation of SNCA, the gene encoding for a-synuclein (Wilson 
et al., 2019). The study employed a radio ligand, [¹¹C] 3-amino-
4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile, to 
assesses with positron emission tomography (PET) the binding 
of serotonergic transporters along with [¹²³I] N-ω-fluoropropyl-
2β-carbomethoxy-3β-(4-iodophenyl) nortropane single photon 
emission computed tomography (SPECT) to evaluate the 
functioning of dopamine transporters. It was observed that 
pre-symptomatic A53T SNCA carriers exhibited decreased 
serotonin binding but unaltered dopaminergic function. In 
pre-symptomatic A53T SNCA carriers, decreased serotonergic 
activity occurred in the raphe nuclei, caudate, putamen, thalamus, 
hypothalamus, and amygdala. Furthermore, in symptomatic 
carriers, the decreased serotoninergic binding was extended 
to the hippocampus, cingulate, insula, and the neocortex in 
conjunction with the appearance of striatal dopaminergic 
deficits. These data support the notion of an early dysfunction of 
the serotoninergic neurotransmission and they are in line with 
the Braak's staging hypothesis that posits a caudorostral gradient 
for the α-synuclein deposition. Unfortunately, the authors of the 
study did not mention the prevalence of VH in their cohorts.
Serotonin neurotransmission encompasses receptors that 
can be divided into seven subtypes (5-HT1 to 5-HT7). These 
receptors are all metabotropic except the ionotropic 5-HT3 
receptor. 5-HT1 receptors are located mostly in raphe nuclei of 
the medulla oblongata, amygdala, and hippocampus (5-HT1A) 
where they work as somatodendritic autoreceptors modulating 
the monoaminergic release and neuroendocrine secretion 
(Pompeiano et al., 1994). 5-HT1D/1B receptors are expressed in 
the caudate, cortex, and SN (Hartig et al., 1992), as well as in 
blood vessels. 5-HT1A and 5-HT1B receptors facilitate dopamine 
release mainly in mesocortical and mesolimbic systems while 
their interaction with nigrostriatal dopaminergic projections is 
controversial (Alex and Pehek, 2007). 5-HT2A/C receptors are 
highly expressed in the prefrontal and anterior cingulate (ACC) 
cortices (Pazos et al., 1985; Fischette et al., 1987) as well as in the 
ventral tegmental area [VTA (5-HT2C)], where they modulate 
dopaminergic release. 5-HT2A/C receptors are strongly 
implicated in the production of VH (see also " Psychedelic 
Drugs") and they are a preferential target in the treatment of 
PD, schizophrenia, depression, drug abuse, and anxiety. 5-HT3 
and 5-HT4 receptors are expressed in the parasympathetic 
terminations of the gastrointestinal system where, by inducing 
acetylcholine release, stimulate motility. These receptor subtypes 
are targeted in the treatment of nausea and vomiting, despite 
some evidence supports the use of 5-HT3 receptor antagonists 
as a treatment for VH (see "Novel Anti-Serotonergic Drugs") 
(Wilde and Markham, 1996; Morales et al., 1998). 5-HT2A 
cortical receptors are part of the serotonergic projections 
that originate from raphe nuclei. Serotonin is also involved 
in the antinociceptive effects, associated with the activation of 
descending projections arising from the periaqueductal gray.
DLB patients, showing VH, exhibit synuclein depositions 
in the dorsal and median raphe nuclei (Benarroch et al., 2007) 
as well as the reduction of serotonin levels in the striatum and 
frontal cortex (Perry et al., 1993a; Ohara et al., 1998; Francis, 
2009). Dense serotonin innervation from dorsal raphe nuclei is 
also found in the intralaminar and higher-order nuclei as well 
as in the LGN (De Lima and Singer, 1987; Vertes et al., 1999; 
Varela, 2014). TRN neurons express 5-HT1A, 5-HT1B, 5-HT2A, 
and 5-HT2B (McCormick and Wang, 1991; Rodríguez et al., 
2011; Shukla et al., 2014) receptors that affect the plasticity 
of thalamocortical synapses (Marek et al., 2001; Barre et al., 
2016). Serotonin excites TRN neurons via 5-HT1C or 5-HT2 
receptors (McCormick and Wang, 1991) and modulates GABA 
release via presynaptic 5-HT1A or 5-HT2A receptors (Goitia 
et al., 2016). Differences in the expression of receptor subtypes 
have been reported when comparing DLB and PD patients with 
or without VH. Previous studies have shown a higher 5HT2 
density, as assessed with audioradiography, in DLB patients with 
VH (compared to patients without VH), in the cortical layers 
III and V of the temporal lobe (Cheng et al., 1991). Moreover, 
post mortem and in vivo studies performed in PD and DLB who 
had suffered from VH, revealed a higher density of 5-HT2A 
receptors within several brain regions of the ventral visual 
pathway (right fusiform gyrus, inferior occipital gyri), together 
with the inferior temporal cortex as well as in frontal regions 
(dorsolateral prefrontal and orbitofrontal cortices) (Huot et al., 
2010). A reduction of serotonin transporter (SERT) expression 
within the basal ganglia (caudate nucleus > putamen) and the 
PCC has also been described (Politis and Niccolini, 2015). 
Increased serotonin signaling turnover has been demonstrated 
by post mortem studies in the brains of DLB patients (Esmaeeli 
et al., 2019). Finally, in the LGN, 5-HT1 presynaptic receptors 
negatively modulate visual inputs to thalamic neurons (Manford 
and Andermann, 1998), thereby inducing a deafferentation-like 
effect that may generate spontaneous VH.
Dopaminergic System
The role of dopamine in the production of hallucinations has 
been extensively investigated in the context of schizophrenia 
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(Miyamoto et al., 2005; Kuepper et al., 2012). The dopamine 
hypothesis of schizophrenia has identified a central role for 
the overactivation of dopaminergic neurotransmission in the 
mesolimbic pathway (Davis and Kahn, 1991). However, a 
successive revision of the theory posits that the dopaminergic 
activation of the nigrostriatal pathway is critical for the production 
of hallucinations (Kuepper et al., 2012). The dopaminergic system 
encompasses five (D1-5) dopamine receptor subtypes that are 
classified into two groups (D1- and D2-like) according to their 
structure and biological effects. The D1-like subtype includes the 
D1 and D5 receptors (D1 and D5) whereas the D2-like subtype 
encompasses the D2 receptors [D2; divided into two isoforms 
(D2-short and D2-long)], the D3 and D4 receptors (D3 and 
D4). All the dopamine receptors are metabotropic (Rangel-
Barajas et al., 2015). The D1-like group is highly expressed in 
the striatum, nucleus accumbens, SN pars reticulata, and the 
olfactory bulb. These receptors are also moderately expressed in 
the entopeduncular nucleus, cerebral aqueduct, and ventricles, 
and they show low density in the dorsolateral prefrontal cortex, 
cingulate cortex, and hippocampus.
The dopamine receptors are involved in the modulation 
of movement as well as in cognitive functions like attention, 
learning, memory, and reward. D2-like receptors are mainly 
expressed in the striatum, external globus pallidus, nucleus 
accumbens, amygdala, cerebral cortex, hippocampus, and 
pituitary gland. These receptors are involved in movement 
control, impulses, and cognition (Mishra et al., 2018). Previous 
studies have suggested that dopaminergic projections originating 
from the SN pars compacta activate the D2 and D4 receptors 
in the TRN, thereby suppressing GABA signaling (Behrendt, 
2006). Molecular investigations have indicated the presence of 
the D1 receptor mRNA in the intralaminar nuclei as well as in 
the lateral geniculate and posterior thalamic nuclei (Fremeau 
et al., 1991). High D2 receptor binding has been found in the 
midline and intralaminar nuclei, and to a lesser degree, in 
primary nuclei and within the TRN (Rieck et al., 2004). D2 and 
D4 agonists decrease the tonic inhibition induced by GABA 
agonists (Yagüe et al., 2013). D4 agonism diminishes the efficacy 
of the GABAergic inhibition exerted by the globus pallidus on 
the TRN (Govindaiah et al., 2010). These findings are in line 
with the studies proposing abnormal functioning of GABAergic/
glutamatergic cortical circuits (Lewis et al., 2005) that triggers an 
excitatory overdrive in the modulation of the SN and increases 
the release of striatal dopamine thus inducing positive symptoms 
(Deutch, 1992; Harden et al., 1998; Kessler et al., 2009).
Thalamic abnormalities in dopaminergic neurotransmission 
have been reported in DLB patients. DLB patients with 
parkinsonism show a significant increase of D2 receptor density 
in the laterodorsal and ventral-intermedius nuclei, whereas DLB 
patients without signs of parkinsonism do not exhibit increased 
D2 density in any brain areas. D2 binding is significantly higher 
in patients with increased extrapyramidal symptoms (Piggott 
et  al., 2007). The striatal density of the dopamine transporter 
(DaT) has also been found to correlate more with motor 
disturbances than with neuropsychiatric symptoms (Ziebell 
et al., 2013; Siepel et al., 2016; Shimizu et al., 2017). Changes in 
the striatal dopamine levels have been found to correlate with 
the DMN activation (Tomasi et al., 2009) and the modulation 
of the attention pathways (Nieoullon, 2002). High striatal DaT 
levels also correlate with the DMN deactivation that occurs upon 
the execution of attention tasks (Ojo and Fernandez, 2016). In 
this setting, decreased dopamine levels have been associated with 
lower deactivation of the parietal component of the DMN (i.e., 
the precuneus) and higher deactivation of the ventral ACC. A 
functional magnetic resonance imaging (fMRI) study analyzed 
the DMN activity and the effects driven by dopaminergic drugs in 
PD patients (Krajcovicova et al., 2012). The study demonstrated 
that subjects treated with a daily administration of levodopa 
increased the functional connectivity of the PCC and decreased 
the DMN activation in the left parahippocampal gyrus upon the 
execution of a cognitive task (Krajcovicova et al., 2012). Another 
study revealed that PD patients deactivate the ventral mPFC of 
the DMN but failed to deactivate the posterior medial and lateral 
areas of the network, a pattern restored by the introduction of 
levodopa (Delaveau et al., 2010).
Cholinergic System
Cholinergic innervation is widespread and essential for cognition 
and autonomic functions. Acetylcholine works on two different 
receptors: muscarinic (MAchR) and nicotinic (NAchR). MAchR 
belong to the family of seven transmembrane receptors coupled to 
G-proteins (Lefkowitz, 2007). In the central nervous system (CNS), 
the muscarinic system plays an essential role in the regulation of 
many sensory, motor, and autonomic processes (Koshimizu et al., 
2012) as well as in learning and memory (Coyle et al., 1983). 
MAchR are sub-divided into five types M1–M5 (Bonner et al., 
1987). MAchR are further categorized into two groups (Hulme 
et al., 1990; Wess et al., 1997). The M1-like subfamily (M1, M3, 
and M5) is coupled to Gαq/11 protein which causes the activation 
of phospholipase C. Whereas the M2-like subfamily (M2 and 
M4) is coupled to Gi/o, which inhibits adenylate cyclase (Matsui 
et al., 2004). NAchR are ligand-gated ion channels formed by the 
assembly of five subunits, around a central pore, in homomeric or 
heteromeric conformation (Dani and Bertrand, 2007).
MAchR and NAchR are part of the basal forebrain and the 
pedunculopontine networks (Mesulam et al., 1983; Gotti and 
Clementi, 2004; Varela and Sherman, 2007). The basal forebrain 
complex arises from the basal nucleus of Meynert and projects 
to the hippocampus, the frontal and prefrontal regions. The 
pedunculopontine system projects to several thalamic and 
midbrain dopaminergic nuclei (Gotti et al., 2006; Carruthers 
et al., 2015). The cholinergic system is a critical modulator of the 
thalamus. The TRN expresses muscarinic (M2) and nicotinic 
(α7) receptors (Court et al., 1999; Carden and Bickford, 1999; 
Quik et al., 2000; Ni et al., 2016). Acetylcholine induces a biphasic 
activity in the TRN, thereby promoting an early depolarization 
(likely dependent on α7 activation) followed by a sustained 
hyperpolarization (due to M2 activation) (McCormick and Prince, 
1986; Sun et al., 2013; Ni et al., 2016). Thalamocortical neurons 
are also influenced by the depolarizing M1 and M3 receptors and 
the hyperpolarizing M2 receptors (Flynn and Mash, 1993; Varela 
and Sherman, 2007). Intrinsic cholinergic neurons also modulate 
the striatum (Gotti et al., 2006). M1, M2, and M4 receptors are 
expressed in the striatum, along with the D2 receptors. The M5 
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receptor, expressed in the VTA, the hippocampus and SN, plays 
an essential role in favoring dopamine release, thereby facilitating 
dopamine-mediated behavioral responses including delirium-like 
sleep behavior disorders and hallucinations (Levey, 1996; Trzepacz, 
1999; Trzepacz, 2000). Finally, the M3 receptor is widely involved 
in the regulation of the release of several neurotransmitters, 
including dopamine, GABA glycine, and endocannabinoids 
(Zhang et al., 2002; Ohno-Shosaku et al., 2003).
The degeneration of cholinergic systems and the basal 
forebrain network are common features of Alzheimer's disease 
(AD), PD, and DLB. This process affects muscarinic and nicotinic 
signaling (Ferreira-Vieira et al., 2016). A correlation between the 
neocortical loss of acetylcholinesterases (AchE) and VH has been 
observed in DLB (Perry et al., 1993; Perry et al., 1999; O'Brien 
et al., 2005). Prominent decrease of α7 expression and increased 
density of α4β2 NAchR in the occipital cortex have been 
described in these patients (Perry et al., 1990 (b); Court et  al., 
2001; O'Brien et al., 2008). A marked decrease (about 50%) of 
α7 NAchR has also been reported in the TRN, thereby offering a 
functional link between the cholinergic imbalance and the TCD 
of DLB patients (Perry et al., 1999). Despite the role of nicotinic 
receptors in the modulation of DLB-related psychotic symptoms, 
to date, drugs interacting with NAchR have not been found to 
impact VH. Interestingly, a recent cross-sectional study assessed 
the in vivo cholinergic activity of pre-symptomatic LRRK2 
carrier PD patients (Liu et al., 2018). When compared to healthy 
controls, symptomatic sporadic and LRRK2 carrier PD patients, 
pre-symptomatic LRRK2 carriers showed a paradoxical increase 
of cholinergic activity occurring the thalamus and DMN-related 
areas, thereby challenging the notion of cholinergic network 
impairment in PD.
Glutamatergic System
Glutamate is the most important excitatory neurotransmitter of 
the CNS. Glutamatergic synapses are involved in cortico-cortical 
(Roland et al., 2014), thalamo-cortical (Alexander et al., 2006), 
striato-cortical (Lassus et al., 2018), and hippocampal (Scherzer 
et al., 1998) networks that mediate key functions like motor control, 
pain perception, memory, and learning. Several neurological and 
psychiatric conditions are related to the presence of glutamatergic 
system dysfunction (Rothman and Olney, 1987). Glutamate binds 
ionotropic and metabotropic receptors. Ionotropic receptors 
are fast-acting and allow the influx of extracellular sodium and 
calcium as well as efflux of potassium ions. Ionotropic glutamate 
receptors are divided into three groups: α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA), some Kainate, and 
N-methyl-D-aspartate (NMDA) receptors (Traynelis et al., 2010).
AMPA receptors are widely expressed in the CNS, mainly 
in post-synaptic regions, where they provide sodium-mediated 
depolarizations. AMPA receptors are tetrameric structures made 
by the heteromeric assembly of four subunits (GluA1–GluA4). 
The GluA2 subunit controls the receptor permeability to 
calcium (Bochet et al., 1994; Jonas et al., 1994; Wright and Vissel, 
2012). The subunit composition controls different biophysical 
properties and pharmacological sensitivity. Calcium-permeable 
AMPA receptors are present in the hippocampus, amygdala, 
and cerebellum where the receptors mediate plasticity processes 
upon brain development (Wiltgen et al., 2010) or are key players 
in the modulation of neurodegenerative conditions (Weiss, 
2000a; Weiss, 2000b; Corona et al., 2011). The interaction 
between AMPA receptors and α-synuclein oligomers in pre- and 
post-synaptic regions have been shown to enhance the AMPA 
receptor-mediated excitotoxic cascade in synucleinopathies 
(Hüls et al., 2011).
Kainate receptors are widely distributed throughout the brain 
in pre- and post-synaptic regions. The receptors are assembled 
as a tetrameric structure containing the GluK1–3 and GluK4–5 
subunits (Traynelis et al., 2010). GLUK subunits show a distinct 
distribution in the CNS. The GluK1-3 subunits are present in the 
CA3 hippocampal subregion, the striatum and the inner layers of 
the cortex whereas the GluK4 and GluK5 subunits show a more 
restricted distribution. GluK4 subunits are almost exclusively 
expressed in the hippocampus (Darstein et al., 2003) while 
GluK5 subunits are found in the striatum and the inner/outer 
layers of the cortex (Gallyas et al., 2003). Kainate receptors affect 
the NMDA receptor-independent long-term potentiation (LTP) 
occurring at the mossy fiber synapses of the CA3 hippocampal 
subregion (Lerma, 2003).
NMDA receptors possess the highest affinity for glutamate and 
have a tetrameric structure. Three families of NMDA receptor 
subunits have been so far identified: 1) NR1, 2) NR2 A-D, 3) 
NR3 A-B (Traynelis et al., 2010). The NR1 subunit is ubiquitously 
expressed in the CNS and controls neurodevelopment as well 
as LTP-related mechanisms (Ju and Cui, 2016). The NR2-A 
subunit is found in the neocortex and hippocampus, while 
NR2-B is primarily expressed in the forebrain (Monyer et al., 
1994). In contrast, the NR2-C and NR2-D subunits are highly 
expressed in the cerebellum, diencephalon, and lower brain stem 
(Rossi et al., 2002). The NR3-A subunits are mainly expressed 
in the neocortex and vary upon development (Das et al., 1998; 
Henson et al., 2008). NR3-B are expressed in the brainstem 
and alpha motor neurons of the spinal cord as well as in the 
cerebellum and hippocampus (Fukaya et al., 2005). Although 
abnormal expressions of a-synuclein and NMDA receptors are 
frequently observed in the hippocampus of patients affected by 
synucleinopathies, the interaction between the two molecules 
remains poorly understood. However, the α-synuclein-driven 
internalization of hippocampal NR1 subunits is involved in 
the cognitive decline or functional impairment of PD and DLB 
patients (Chen et al., 2015).
Metabotropic glutamate receptors (mGluR 1–8 receptors) are 
classified in three groups depending on the binding specificity, 
ionic modulation, and conductance properties: group 1 
(mGluR1 and mGluR5), group 2 (mGluR2 and mGluR3), and 
group 3 (mGluR4, mGluR6, mGluR7, and mGluR8) (Traynelis 
et al., 2010). Group I metabotropic receptors are largely expressed 
on postsynaptic membranes and have been associated with the 
modulation of learning, memory, addiction, and movement 
(Niswender and Conn, 2010). Group II metabotropic receptors 
are expressed in pre- and post-synaptic regions where they 
influence glutamate transmission. Dysfunctions in the activity 
of group II metabotropic receptors have been implicated in 
the modulation of anxiety, schizophrenia, and AD (Swanson 
et al., 2005). Group III metabotropic receptors are pre-synaptic 
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and inhibit neurotransmitter release. Group III receptors are 
expressed in the hippocampus and hypothalamus and may 
play a role in PD and DLB as well as in anxiety disorders 
(Dalfó et al., 2004; Swanson et al., 2005). Glutamatergic 
synapses interact with dopaminergic and serotoninergic 
systems and play an important role in the genesis of auditory 
hallucinations (Sommer et al., 2018) and VH. In that respect, 
the hypofunction of NMDA receptors along with the 
overactivation of D2 and 5-HT receptor subtypes has been 
indicated to converge in producing VH and other psychotic 
symptoms (Rolland et al., 2014).
Moreover, according to a recent model (Grace, 2016), the 
NMDA receptor activation modulates the activity of parvalbumin-
positive GABAergic interneurons located in the ventral subiculum. 
The activation of parvalbumin-pyramidal neurons is needed to 
drive gamma rhythmic activity, thereby providing an inhibitory 
input to pyramidal neurons. The NMDA receptor inhibition 
produces an overdrive of the nucleus accumbens which inhibits 
the ventral pallidum and increases the excitability of dopaminergic 
neurons of the lateral VTA that projects to the associative striatum, 
thereby generating VH. This model explains the presence of 
positive symptoms, including VH, in conditions like the anti-
NMDA receptor autoimmune encephalitis, schizophrenia, and 
PD-related anxiety (Kuppuswamy et al., 2014; Barry et al., 2015).
GABAergic System
GABA is the principal inhibitory transmitter of the CNS. GABA acts 
through the activation of three receptor subtypes: GABA-A (Curtis 
and Johnston, 1974; Johnston, 1996), GABA-B, and GABA-C 
(Chebib and Johnston, 1999; Tritsch et al., 2016). GABA-A and 
GABA-C receptors are ionotropic, whereas GABA-B is metabotropic. 
GABA-A receptors, which are transmembrane protein complexes 
made up of five subunits, produce most of the physiological actions 
of GABA (Sieghart et  al., 1999). Many drugs modulate distinct 
allosteric binding sites on these receptors in order to produce 
clinically relevant effects in epilepsy, anxiety, and sleep disorders 
(Smith and Olsen, 1995). A recent study employing magnetic 
resonance spectroscopy revealed reduced GABA concentrations in 
the visual cortex of PD patients exhibiting complex VH (Firbank 
et al., 2018). These data are in agreement with neuropathologic 
findings showing reduced GABAergic activity in the visual cortex 
of DLB patients (Khundakar et al., 2016). DLB and PDD patients 
show glucose hypometabolism and hypoperfusion in the medial 
occipital lobe, including the primary and secondary visual cortices 
(Khundakar et al., 2016). The reduction in GABA levels has been 
suggested to serve a role in optimizing the visual processing in the 
presence of poor input to the visual cortex. The process can be carried 
out at the price of increasing the misclassification of ambiguous 
stimuli (Bowman et al., 2017). However, recent evidence indicates 
no correlations between alterations of GABA levels and the severity 
of VH, thereby implying that other factors, like the processing of 
visual stimuli and attention, play a role in favoring the generation 
of hallucinations (Firbank et al., 2018). Nevertheless, alterations 
in GABAergic transmission may contribute to the dysfunctional 
integration of perceptual and attentional processing, mechanisms 
that are involved in the production of VH (Shine, 2014).
PHARMACOLOGiCAL MODULATORS OF 
ViSUAL HALLUCiNATiONS: iNDUCiNG 
DRUGS
Psychedelic Drugs
As mentioned above, the production of hallucinations and 
psychotic-like symptoms has been investigated by many 
pharmacological studies employing psychedelic drugs like LSD, 
mescaline, psilocybin, and ayahuasca (Geyer and Vollenweider, 
2008). LSD produces visual, auditory, cenesthetic hallucinations, 
ego-, bodily, and time-related distortions as well as derealization 
and depersonalization (Nichols, 2016) (Linton, 1962). The 
molecule exhibits complex pharmacology and modulates 
serotonergic, dopaminergic, and glutamatergic transmissions. 
The activation of the 5-HT2A receptors in the pyramidal 
neurons of the prefrontal and limbic cortex is now considered 
the most critical mechanism for the LSD-driven production of 
schizophrenia-like hallucinations (Passie et al., 2008; Eggers, 
2013; Kometer and Vollenweider, 2018). The LSD-driven 
modulation of dopaminergic neurotransmission appears to 
have a lesser role in the production of psychedelic effects. LSD 
exhibits both agonistic and antagonistic effects on D1 and D2 
dopaminergic receptors although neurophysiological studies on 
animal models have indicated a dose-dependent LSD inhibition 
of the mesolimbic dopamine firing (von Hungen et al., 1974; De 
Gregorio et al., 2016).
Psilocybin is an alkaloid tryptamine found in mushrooms 
like the Psilocybe mexicana (Passie, 2002). In vivo, psilocybin is 
dephosphorylated to psilocin. Psilocybin induces psychedelic 
effects by promoting the activation of 5-HT2A, 5-HT2C, 
and 5-HT1A receptors (Wolbach et al., 1962). Illusions, 
synesthesias, altered sense of space and time, proprioceptive 
alterations are common effects triggered by psilocybin (Geyer 
and Vollenweider, 2008; Carhart-Harris et al., 2010; Turton 
et al., 2014). Functional neuroimaging studies, performed after 
psilocybin administration, have shown increased functional 
connectivity between the DMN and TPNs as well as decreased 
oscillatory activity within the PCC (Muthukumaraswamy et al., 
2013; Carhart-Harris et al., 2013). The PCC exhibits a high 
density of 5-HT2A receptors. The decrease of the region intrinsic 
alpha firing rhythm correlates with the occurrence of psychedelic 
effects like ego disturbance and spatial and temporal distortions 
(Passie et al., 2008). Neuroimaging studies investigating the 
metabolic changes occurring after psilocybin administration 
have revealed the presence of thalamic hyperactivity along with 
the reduction in orbitofrontal and ACC metabolism in subjects 
showing signs of anxiety-driven ego-dissolution (Carhart-Harris 
et al., 2012; Lebedev et al., 2015; Nichols, 2016). The severity of 
visual abnormalities, including VH, has also been associated 
with the presence of increased metabolism in the left dorsolateral 
prefrontal and temporo-parietal cortex, while decreased 
metabolism has been reported in the parahippocampal, fusiform, 
and lingual gyrus (Vollenweider and Geyer, 2001b).
Ayahuasca (in the Quechua language "vine of the souls") 
(McKenna et al., 1984) is a psychedelic substance employed by 
Amazonian native Americans to produce mystic and meditative 
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states of consciousness (Palhano-Fontes et al., 2015). Ayahuasca 
is typically administered as an infusion of Banisteriopsis caapi 
liana and Psychotria viridis plants (Palhano-Fontes et al., 2015). 
While Psychotria contains N, N-dimethyltryptamine (DMT), 
B. caapi is enriched with psychoactive β-carbolines alkaloids 
like harmine, tetrahydroharmine, and harmaline (McKenna 
et al., 1984; Palhano-Fontes et al., 2015). DMT is an agonist 
of the 5-HT1A, 5-HT2A, and 5-HT2C receptors (Ray, 2010; 
Cameron and Olson, 2018). The compound is also endogenously 
synthesized from tryptophan, serotonin, or melatonin, and 
rapidly inactivated by monoamine oxidases (Cameron and 
Olson, 2018). Therefore, DMT-driven psychedelic effects can 
appear in subjects treated with monoamine oxidase inhibitors 
(MAO-I) (Palhano-Fontes et al., 2015). DMT can also bind and 
activate the stress-responsive sigma 1 receptors that are involved 
in neuroplasticity and neuromodulatory functions (Inserra, 
2018). The ayahuasca effects include the production of increased 
introspection, VH, perceptive, affective, somatic, and cognitive 
changes (Riba et al., 2001). Antidepressant effects have also 
been reported after sporadic administration of the compound 
(Domínguez-Clavé et al., 2016). fMRI-based studies, performed 
after ayahuasca administration, have revealed decreases in DMN 
activity and functional connectivity occurring in the precuneus 
and PCC (Palhano-Fontes et al., 2015). The phenomenon has 
been suggested to reinforce "meditative efforts" and counteract 
the mind-wandering related to the DMN activation (Palhano-
Fontes et al., 2015). Ayahuasca-driven increases in brain 
metabolism in the bilateral insular and right ACC as well as in 
frontal regions have been also reported (Riba et al., 2006). These 
findings are consistent with the enhanced emotional processing 
promoted by the compound (Riba et al., 2001).
Antidepressants
Antidepressants modulate the monoaminergic neurotransmission 
and exhibit a prominent activity on noradrenaline and serotonin 
signaling. This class of compounds promotes: 1) the inhibition 
of the transmitter reuptake [as in the case of selective serotonin 
reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake 
inhibitors (SNRI), noradrenaline reuptake inhibitors (NaRI), 
or tricyclic antidepressants (TCA)]; 2) the inhibition of 
catabolic enzymes (as in the case of MAO-I), 3) the blockade 
of α2-presynaptic receptors [as for noradrenergic and specific 
serotonergic antidepressants (NaSSA)]; 4) the enhancement of 
dopaminergic transmission. Atypical antidepressants combine 
these effects by acting synergistically on different receptor 
subtypes. Antidepressants exhibit unclear and contradictory 
effects on the production of hallucinations and psychosis.
Individual cases of patients who developed VH after 
receiving fluoxetine have been reported (Omar et al., 1995). 
Moreover, it has been suggested that the drug action on ventral 
striatal areas stimulates 5-HT3 receptors, promotes enhanced 
dopamine release from the ventral striatum, and therefore 
produces psychosis (Lauterbach, 1993). Antagonistic effects 
on 5-HT2C receptors that tonically inhibit dopamine release 
in nigrostriatal and mesolimbic pathways may also be involved 
(Alex and Pehek, 2007). TCA have consistently shown to 
produce hypnopompic or hypnagogic hallucinations, an effect 
likely due to the drug interference on the sleep architecture 
along with their anticholinergic effects (Cancelli et al., 2004). 
Amitriptyline, clomipramine, and imipramine have also found 
to induce VH and auditory hallucinations and worsening of 
psychotic symptoms (Klein, 1965; Baldessarini and Willmuth, 
1968; Vallada and Gentil, 1991). Finally, it should be mentioned 
the possible onset of VH due to discontinuation syndrome, 
which can be triggered by the cessation of almost all classes of 
antidepressants (Yasui-Furukori N and PhD and Kanek, 2011).
Dopaminergic Agents
Dopaminergic drugs, such as levodopa and dopamine agonists, 
are commonly used to manage parkinsonian motor symptoms. 
These agents are, however, also associated with the occurrence of 
significant motor and behavioral side effects. VH are sometimes 
a side effect of treatment (Fénelon, 2006) especially with 
dopamine agonists, compounds that promote an overactivation 
of the mesolimbic dopamine D2 and D3 receptors (Wolters, 
1999; Burghauset al., 2012). While the duration and dosage of 
the dopaminergic therapy loosely fit with the appearance of VH 
(Ojo and Fernandez, 2016), VH are managed by decreasing the 
dosage or the use of antipsychotics.
The catechol-O-methyl-transferase (COMT) is an intracellular 
enzyme that catalyzes the transfer of the methyl group from 
S-adenosyl-L-methionine to one of the hydroxyl groups of a 
catechol substrate. COMT inhibitors (i.e., tolcapone, entacapone, 
opicapone) are widely employed to treat PD patients (Kaakkola, 
2000). This class of drugs has not been directly linked to VH. 
However, as the molecules affect levodopa metabolism and 
increase its bioavailability, they may worsen the levodopa side 
effects, including VH (Kaakkola et al., 1994; Onofrj et al., 2001).
The Monoamine Oxidase Inhibitor B (MAOI-B) is the 
primary catabolizing enzyme for dopamine in the brain (Yamada 
and Yasuhara, 2004). Rasagiline and selegiline are two inhibitors 
of the MAOI-B employed in PD patients to enhance the striatal 
levels of dopamine. In the TVP-1012 in early monotherapy for 
Parkinson disease outpatients (TEMPO) study, hallucinations 
and confusion have been reported to occur with equal frequency 
in rasagiline- or placebo-treated PD patients (Siderowf et al., 
2002). In the Parkinson's Rasagiline: efficacy and safety in the 
treatment of off (PRESTO), where rasagiline was used as an 
add-on to levodopa, the drug produced only a mild increase in 
hallucinations (4%) (Parkinson Study Group, 2005) compared 
to placebo (3.1%). There is conflicting evidence about the 
selegiline role in VH induction. Long-term selegiline-related 
studies have indicated that the incidence of psychotic side effects 
of the compound is similar to placebo (Myllylä et al., 1997). 
However, a sudden increase in the incidence of hallucinations 
has been reported in some PD patients upon the introduction 
of selegiline (Kamakura et al., 2004). It should be stressed that 
these patients, before the introduction of selegiline, were at a 
relatively late stage of the disease and treated with high doses of 
levodopa along with dopamine agonists, thereby suggesting that 
a complex pharmacological interaction is behind the presence of 
VH (Kamakura et al., 2004).
Frontiers in Pharmacology | www.frontiersin.org December 2019 | Volume 10 | Article 1379
Visual Hallucinations in SynucleinopathiesRusso et al.
11
Anticholinergic Drugs
Anticholinergic drugs are known to trigger VH (Goetz et  al., 
1982). The effect is well known in the case of agents with 
strong anti-muscarinic activity like atropine, scopolamine, 
and hyoscyamine. These compounds have been known for 
centuries to promote potent psychotropic effects, including 
delirium-like states, hallucinations, mood alterations, and 
cognitive deficits (Lakstygal et al., 2018). Atropine is extracted 
from Atropa belladonna and is a non-selective anti-muscarinic 
agent (Lakstygal et al., 2018). Atropine crosses the blood-brain 
barrier (BBB) and rapidly induces the occurrence of restlessness, 
memory-impairing effects, mental agitation/excitement, and 
hallucinations (Hammon and DeMartino, 1985; Inzelberg et al., 
1990). Scopolamine is another non-selective anti-muscarinic 
agent that affects attention, sensory/stimulus discrimination, 
locomotion, and anxiety (Smythe et al., 1996; Luyten et al., 
2017). The occurrence of transient psychosis has been described 
in patients undergoing treatment with scopolamine patches 
(Zhang et al., 2017). Hyoscyamine is the levorotatory form 
of racemic atropine and acts as a nonselective competitive 
antagonist of the muscarinic receptor (Soni et al., 2012). The 
compound generates psychomotor effects that resemble those 
triggered by atropine and scopolamine and include hyperactivity, 
motor paralysis, loss of voluntary coordination, spatiotemporal 
disorientation, depersonalization, memory impairment, sleep, 
and hallucinations/delirium-like states (Keeler and Kane, 1967). 
Oxybutynin, tolterodine, trospium chloride, and propriverine are 
other anticholinergic drugs used to treat detrusor hyperreflexia 
(Malkowicz et al., 1987; Gulsun et al., 2006) and associated with 
cognitive and behavioral side effects (Fick et al., 2003; Scheife 
and Takeda, 2005; Gulsun et al., 2006).
N-Methyl-D-Aspartate Receptor Antagonists
Ketamine is a non-competitive NMDA receptor antagonist. First 
introduced as an anesthetic, the compound has also been employed 
as a recreational drug for its hallucinatory and dissociative effects 
(Hocking and Cousins, 2003; Correll et al., 2004; Rasmussen et al., 
2013). In anesthetic and sub-anesthetic doses, the molecule produces 
auditory verbal hallucinations (Rasmussen, 2014). Some studies 
have indicated that the NMDA receptor blockade is sufficient to 
induce the psychomimetic effects (Pitcher et al., 2011). However, the 
compound also works through the activation of 5-HT2A receptors 
(Dall'Olio et al., 1999; Rolland et al., 2014). Ketamine affects the 
functional connectivity of the DMN and the sensorimotor network 
(Niesters et al., 2012; Driesen et al., 2013). Interestingly, ketamine 
shows specific, distinct, and dose-dependent effects on resting-state 
networks (Bonhomme et al., 2016). At lower doses, the molecule 
alters the connectivity of the dorsolateral prefrontal cortex, a region 
that is implied in the modulation of working memory while, at high 
doses, impairs the functional connectivity of the fronto-parietal 
cortex (Höflich et al., 2015).
Phencyclidine (PCP) is a non-competitive NMDA receptor 
antagonist that, like ketamine, induces schizophrenia-like 
symptoms. The two drugs are therefore also known as "dissociative 
anesthetics." In addition to NMDA receptor antagonism, PCP 
also activates the opioid sigma-1 receptor, but the role of this 
interaction in the production of the hallucinogenic effects is still 
not completely clear (Mori and Suzuki, 2018).
Memantine is a low-affinity NMDA receptor antagonist, 
employed as symptomatic treatment of patients suffering from 
moderate to severe AD (Lorenzi et al., 2011). Memantine has been 
tested in PD-DLB as a neuroprotectant, but its use is significantly 
limited by the substantial risk of inducing psychotic side effects 
(Riederer et al., 1991). The majority of studies, involving DLB and 
PD patients treated with memantine, have indicated worsening of 
the psychotic symptoms, including the occurrence of delusions 
and hallucinations (Kim et al., 1980; Menendez-Gonzalez et al., 
2005; Lipton, 2006) while only one study has shown improvement 
in the Neuropsychiatric Inventory scores (Ridha et al., 2005).
Amantadine, an anti-influenza drug (Liepert, 2016) and 
a weak NMDA receptor antagonist, is used as an add-on drug 
to treat the dyskinesias and freezing gait of PD patients. The 
pharmacodynamic properties of the drug are still unclear. 
The compound modulates the release of monoamines and has 
some neuroprotective effects (Farnebo et al., 1971; Kornhuber 
et al., 1994). Several reports have indicated the presence of 
amantadine-induced hallucinations or other psychotomimetic 
and neuropsychiatric side effects (Harper and Knothe, 1973; 
Postma and Van Tilburg, 1975; Smith, 2008; Walsh and Lang, 
2012). Therefore, the use of amantadine in PD patients should be 
restricted to subjects with no history of psychiatric disturbances.
Propofol is mainly a GABA-A receptor agonist, but the 
compound also acts as an NMDA receptor antagonist. Propofol has 
been associated with the production of post-surgery hallucinations 
characterized by distinct sexual content, the occurrence of 
uninhibited behavior, and the verbal expression of the patient most 
intimate thoughts (Martínez Villar et al., 2000; Felfernig et al., 
2006; Marchaisseau et al., 2008). Like ketamine, propofol affects 
the activity of the DMN and decreases the connectivity among the 
network nodes with different potency (Liu et al., 2015).
Opioids
The opioid system is mostly involved in the regulation of pain 
perception (Al-Hasani and Bruchas, 2011; Stein, 2016; Valentino, 
2018). Several observations have also indicated a role for opioids 
in the induction of VH (Sivanesan et al., 2016; Tan and Gan, 
2016), although only a few studies have so far dissected the 
mechanisms underlying the psychoactive properties of the 
compounds. Early reports have associated the hallucinogenic 
properties of opioids with the activation of σ receptors (Sivanesan 
et al., 2016). However, the σ receptor is no longer considered 
an opioid receptor (Hayashi and Su, 2005) because it is bound 
by different classes of psychotropic drugs as well as by sexual 
hormones, haloperidol, and other substances (Hayashi and Su, 
2005). The opioid receptors (OR) include the µ (MOR), κ (KOR), 
and δ (DOR) receptor subtypes (Al-Hasani and Bruchas, 2011; 
Shang and Filizola, 2015). The OR-like receptor 1 (ORL-1), 
also called nociceptin, has also been included in the OR family 
(Waldhoer et al., 2004; Al-Hasani and Bruchas, 2011). OR are 
coupled to G-proteins and expressed with calcium channels in 
the hippocampus, locus coeruleus, VTA, and dorsal root ganglia 
(Al-Hasani and Bruchas, 2011). The opioid-mediated regulation 
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of synaptic transmission, obtained through a reduction of calcium 
currents and vesicular storage, has been described to occur after 
acute opioid administration (Al-Hasani and Bruchas, 2011). OR 
mediate the analgesic properties exerted by endogenous and 
most of the exogenous opioids. OR subtypes produce distinct 
mood alterations. MOR agonists induce euphoria (Stein, 2016), 
whereas DOR activation causes anxiolytic effects (Stein, 2016; 
Valentino and Volkow, 2018). The activation of κ receptors has 
been associated with the production of dysphoric feelings as well 
as with sedative effects (Wang et al., 2010; Maqueda et al., 2015; 
Valentino and Volkow, 2018).
The link between κ receptors and VH is still unclear, but 
increasing interest is arising in κ receptor-mediated hallucinogenic 
properties of salvinorin-A (Chavkin et al., 2004; Babu et al., 2008; 
Maqueda et al., 2015). Salvinorin-A is a κ receptor agonist that 
binds to the dynorphin site (Roth et al., 2002). Preclinical models 
have also indicated an interaction of the compound with the 
cannabinoid CB1 receptor (Braida et al., 2007). The molecule, a 
non-nitrogenous neoclerodane diterpene (Chavkin et al., 2004), 
has been found in the plant Salvia divinorum (Maqueda et al., 
2015). The name of the plant originates from the Mazatecs ancient 
beliefs regarding the spiritual and mystic properties of S. divinorum 
(Addy, 2012). Salvinorin-A has been described to produce dose-
dependent alterations in body sensation and awareness, visual-
auditory, and visual-proprioceptive synesthesia, depersonalization, 
derealization, and mood changes as well as complex visual and 
auditory hallucinations (Maqueda et al., 2015). Functional studies 
indicate that the compound acts on the medial parietal DMN and 
thalamus (Maqueda et al., 2015). Morphine, fentanyl, oxycodone, 
and tramadol are commonly associated with the occurrence of VH 
(even upon drug withdrawal) (Rajabizadeh et al., 2009); however, 
experimental evidence is missing regarding the pathophysiological 
underpinnings of the phenomena (Moore, 2003; Pellegrino et al., 
2013; Colak et al., 2015; Sverrisdóttir et al., 2015).
Other Visual Hallucinations-Inducing Drugs
Calcium blockers poorly permeate the BBB, but they have 
been reported to trigger hallucinations, especially in the case 
of verapamil and diltiazem (Kumar et al., 1988; Bushe, 1988). 
The underlying mechanisms are still unclear, but an inhibitory 
effect on mitochondrial calcium efflux and neurotransmitter 
release has been suggested (Matlib, 1983). Alterations in 
calcium signaling have been implicated in psychiatric disorders 
such as schizophrenia and found to affect GABAergic neurons 
as well as the synchronization of brain rhythms (Berridge, 
2014). The activity of tyrosine hydroxylase, the rate-limiting 
enzyme in catecholamine synthesis, is increased by calcium 
chelation in dopaminergic neurons (Bushe, 1988). Delirium and 
hallucinations are well-known side effects triggered by the use 
of different groups of antibiotics. Beta-lactams, and in particular 
carbapenems, cause inhibition of the GABA-A receptor in the 
CNS as well as disinhibition of the DMN (Looijestijn et al., 
2015; Veillette and Van Epps, 2016). Similar GABA-A receptor-
mediated mechanisms are involved in quinolones-related 
hallucinations (Grill and Maganti, 2011; Chauhan et al., 2013). 
Trimethoprim-sulfamethoxazole may also cause VH (Stuhec, 
2014) with still unclear mechanisms. Among antifungal agents, 
voriconazole and posaconazole have been associated with VH 
(Agrawal and Sherman, 2004; Imataki et al., 2008; Parkes et al., 
2016). Ketoconazole has been associated with the occurrence of 
tactile hallucinations, and in particular delusional parasitosis, 
phenomena due to the antagonism of the glucocorticoid receptors 
and an increase in corticotropin-releasing factor levels. The 
latter induces a concentration-dependent increase in dopamine 
synthesis and dopamine dysregulation in the basal ganglia is a 
well-established cause of psychotic symptoms (Fisch and Lahad, 
1989; Huber et al., 2007).
TReATMeNT OPTiONS FOR ViSUAL 
HALLUCiNATiONS
Novel Anti-Serotonergic Drugs
5-HT receptor blockade attenuates VH and psychotic symptoms 
in PD and DLB patients (Meltzer et al., 2010). This mechanism is 
exploited by pimavanserin, an inverse agonist of 5-HT2A receptors, 
as well as by clozapine, quetiapine, and other atypical antipsychotic 
drugs. Pimavanserin negligibly binds dopaminergic, adrenergic, 
histaminergic, and muscarinic receptors, thereby producing an 
almost pure antiserotonergic effect (Cruz, 2017). These positive 
effects of pimavanserin in the treatment of VH occur, most likely 
because of the lack of D2 antagonist properties shown by the 
compound, without producing worsening of motor functions, 
sedation, or hypotensive effects (Cummings et al., 2014; Fox, 2014). 
Pimavanserin is preferable compared to other atypical antipsychotics 
for its safety profile and selective activity. Pimavanserin has been 
approved by the Food and Drug Administration as a first-line 
intervention drug for the treatment of delusions and hallucinations 
in PDD patients.
Ondansetron is a selective 5-HT3 receptor antagonist employed for 
the treatment of nausea and vomiting associated with chemotherapy, 
radiotherapy, anesthesia, or surgery (Wilde and Markham, 1996). 
Two small open-label studies investigating the use of ondansetron 
in PD patients found positive effects on VH and delusions (Zoldan 
et al., 1993; Zoldan et al., 1995). The efficacy of ondansetron 
against hallucinations has been associated with the blockade of the 
neuronal 5-HT3 receptors present in the area postrema, nucleus 
tractus solitarius, amygdala, and dorsal raphe nucleus (Wilde and 
Markham, 1996). Ondansetron does not induce worsening of motor 
symptoms and produces mild and reversible side effects (Zoldan 
et al., 1993). Ondansetron also has been successfully employed as an 
add-on drug to other antipsychotics for the treatment of the negative 
symptoms in schizophrenia (Allisoc, 2010). However, other studies 
have contended that these positive effects are transient and may fade 
away with the continuation of therapy (Eichhorn et al., 1996).
Typical Antipsychotics
First-generation or "typical" antipsychotics, employed to 
manage the positive symptoms of schizophrenic patients, 
were designed to exert D2 receptor antagonism and inhibit 
the dopaminergic neurotransmission in mesocortical, 
mesolimbic, nigrostriatal, and tuberoinfundibular pathways. 
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These compounds promote a postsynaptic blockade of D2 
receptors in the cortex and striatum (Seeman, 2002; Stone 
et al., 2009). As discussed above (Perry et al., 1990, 1990a); 
Diederich et al., 2005), VH associated with synucleinopathies 
are the result of a complex monoaminergic imbalance 
involving dopamine and serotonin pathways (Perry et  al., 
1990, 1990 a), but the role of dopamine in VH is less prominent 
than schizophrenia. Several studies indicate that the thalamic 
D2 receptor density is associated more with parkinsonism 
than VH, a notion supported by findings indicating that the 
striatal DaT density correlates more with motor disturbances 
than neuropsychiatric symptoms (Ziebell et al., 2013; Siepel 
et al., 2016; Shimizu et al., 2017). The use of antipsychotics is 
associated with severe side effects in patients with DLB. This 
feature, called "severe neuroleptic sensitivity," includes the 
presence of cognitive decline, parkinsonism, drowsiness, as 
well as the neuroleptic malignant syndrome (Ballard et al., 
1998). Typical antipsychotics employed for VH may worsen the 
extrapyramidal symptoms of PD patients and are therefore not 
recommended. Moreover, compared to atypical antipsychotics 
like quetiapine, olanzapine, and risperidone, haloperidol has 
been associated with a higher mortality rate of PD patients 
(Weintraub et al., 2016).
Atypical Antipsychotics
Clozapine is the prototype of the atypical antipsychotics 
(AA) class that encompasses olanzapine, quetiapine, 
and risperidone. The AA have different side effects and 
display different tolerability properties but share similar 
pharmacodynamic and pharmacokinetic characteristics. AA 
exhibit high-affinity inhibition of the 5-HT2 receptor, low-
affinity inhibition of the D2 receptor, and 5-HT1 receptor 
agonism (Kapur and Seeman, 2001). The main action of AA 
is mediated through the interaction with 5-HT receptors 
(Meltzer and Massey, 2011). Because of its high tolerability in 
the elderly and the paucity of severe adverse effects, quetiapine 
is still is the most commonly prescribed antipsychotic drug 
in PD and PDD patients (Takahashi et al., 2003; Rabey et al., 
2007; Desmarais et al., 2016). The administration of clozapine, 
although considered very useful (Tuunainen et al., 2002; 
Eng and Welty, 2010), is restricted by the presence of severe 
adverse effects driven by the drug anticholinergic properties 
(Kapur and Seeman, 2001; Tuunainen et al., 2002; Eng and 
Welty, 2010). Because of the lower efficacy and the increased 
rate of side effects, olanzapine and risperidone are less used 
in PD and DLB (Cummings et al., 2002; Ondo et al., 2002; 
Panchal and Ondo, 2018).
Acetylcholinesterase inhibitors
Acetylcholinesterase inhibitors (AchE-I), such as donepezil, 
rivastigmine, and galantamine, inhibit the breakdown 
of acetylcholine, thereby potentiating cholinergic 
neurotransmission (Colović et al., 2013). AchE-I are employed in 
mild to moderate AD and produce transient ameliorating effects 
in cognition and behavioral symptoms, including VH (Onofrj 
et al., 2003; Birks, 2006; Ferreira-Vieira, 2016). AchE-I have also 
been employed in PD patients showing cognitive impairment 
and/or apathy or in DLB patients with VH (McKeith, 2000; 
Burn et al., 2006; Poewe et al., 2006). PDD and DLB patients 
exhibit relative hypoperfusion in the parietal and occipital 
brain regions (Collerton et al., 2005) and the AchE-I-driven 
increased perfusion of the PCC has been suggested to play a role 
in improving the attention to visual stimuli and decrease the 
VH frequency in these subjects (McKeith et al., 2004; O'Brien 
et al., 2005). Finally, AA that are effective in treating DLB 
hallucinations and also promote an increase of extracellular 
acetylcholine levels (Shirazi-Southall et al., 2002).
Other Possible Treatments for Visual Hallucinations
The use of antidepressants has been often associated with 
VH induction. However, a study carried out on a cohort of 
692 patients affected by either AD or vascular and/or mixed 
dementia found that citalopram and sertraline show some 
efficacy against agitation or psychosis (Seitz et al., 2011). 
Within the atypical antidepressants, mirtazapine, a compound 
most likely acting via antagonism of the α2, 5-HT2, and 5-HT3 
receptors, has been successfully employed to treat VH and 
auditory hallucinations in PD patients (Golden et al, 1998; 
Nagata et al., 2013; Tagai et al., 2013).
Vortioxetine, one of the newest antidepressants, is a SRI. 
The compound is also an antagonist of 5-HT1D, 5-HT3, and 
5-HT7 receptors as well as agonist of 5-HT1A and partial 
agonist of 5-HT1B receptors (D'Agostino et al., 2015; Stahl, 
2015). Vortioxetine also exhibit cholinergic activity that may be 
indicated for synucleinopathy-associated patients showing VH 
and affective disturbances (Smart et al., 2018).
No worsening of VH has been reported in advanced PD 
patients treated with apomorphine (García Ruiz et al., 2008; 
Borgemeester et al., 2016), a drug with antipsychotic effects 
(Smith, 1977; Tamminga et al., 1978). Apomorphine is a potent 
dopamine agonist with high affinity for the D1- and D2-like 
receptors (Millan et al., 2002). The antipsychotic activity is likely 
due to the presence of a piperidine moiety, which has antagonist 
activity on serotonergic receptors and the 5-HT2A-receptor 
subtype in particular (Ellis et al., 1997).
Finally, naloxone, an opioid antagonist, is effective in 
abrogating auditory and VH in schizophrenic patients 
(Gunne et al., 1977), findings that are consistent with the 
role of the  endogenous opioid system in the induction and 
resolution of VH.
CONCLUSiONS
VH are common features of PD and DLB (Halliday et al., 2011). 
Many questions on the pathophysiology of these phenomena are 
still open. Early observations suggesting an iatrogenic origin for 
the VH found in synucleinopathies (Moskovitz et al., 1978) have 
been now disconfirmed by the fact that in many cases VH appear 
with appropriate therapeutic courses or even in the absence of 
any pharmacological therapy. Moreover, several findings have 
also confirmed the notion that, in PD and DLB patients, the 
synuclein-driven deregulation of brain circuits and functional 
networks predispose to VH.
Frontiers in Pharmacology | www.frontiersin.org December 2019 | Volume 10 | Article 1379
Visual Hallucinations in SynucleinopathiesRusso et al.
14
The development of concepts as "metastability" of cognition 
and "entropic brain," proposed by Carhart-Harris and Coll. 
(Carhart-Harris et al., 2014), has been crucial milestone of the 
research in the field. This notion has indeed allowed a better 
understanding of the link between the TCD, already observed 
by Llinàs and Coll. in the 90s (Llinàs et al., 1999) and the 
development of the clinical symptoms exhibited by PD or DLB 
patients, an array ranging from cognitive fluctuations to VH. 
These findings have led to posit the current model of VH in 
synucleinopathies (Onofrj et al., 2019) which are considered to 
result from PPN-driven alterations of thalamic pacing due to the 
enhanced activity of TRN. The derangement of thalamocortical 
loops provokes the unleashing of the DMN that becomes 
disentangled from the control of the TPNs.
Several neurotransmitters have been implied in the 
development of VH. Serotonergic agents, like psychedelic 
drugs, have been proven to actively participate in the 
phenomenon also in healthy subjects (Geyer and Vollenweider, 
2008). In particular, the activation of 5HT2A receptors 
which are expressed with high density in the PCC, a hub of 
DMN, has been strongly linked with the VH onset (Passie 
et al., 2008; Carhart-Harris et al., 2010). Alterations of the 
serotonergic system are a typical finding in synucleinopathies 
(Seidel et al., 2015; Wilson et al., 2019). Moreover, 
antipsychotic drugs modulating serotonergic transmission 
are now widely employed to treat VH, especially in PD and 
DLB patients (Carrarini et al., 2019). Further investigations 
will be nevertheless needed to clarify the fine downstream 
mechanism involved in these processes.
In addition, cholinergic impairment is also exerting a 
major role (Ferreira-Vieira et al., 2016) as muscarinic and 
nicotinic receptors have been found to be expressed in the 
thalamus, and in particular within the TRN (Quik et al., 2000; 
Ni et  al., 2016). Cholinergic transmission may influence the 
onset and maintenance of TCD, thereby favoring VH (Varela 
and Sherman, 2007). In that context, AchE-I by increasing the 
extracellular levels of acetylcholine may be of therapeutic value 
and reduce VH in DLB patients (Shirazi-Southall et al., 2002), 
an effect also possibly due to ameliorating PCC perfusion 
(McKeith et al., 2004; O'Brien et al., 2005). On the other hand, 
anticholinergic drugs, as atropine can trigger VH (Goetz et al., 
1982) and should, therefore, avoided in elderly patients when 
there is a suspect of underlying synucleinopathies.
A special role is played by the alterations of the 
dopaminergic system, the main target of the disruptive effect 
of a-synuclein. Although dopamine replacement therapy is 
a pillar for the treatment of the motor symptoms of PD and 
DLB, the neurotransmitter unfortunately also exacerbates 
some neuropsychiatric disorders associated with the disease 
like VH, impulse control disorders, and overall behavioral 
changes (Fénelon, 2006). It is now clear that dopamine 
therapy, especially at high dosage, can trigger VH by acting 
on the nigrostriatal pathway (Kuepper et al., 2012). Careful 
management of dopamine replacement therapy is therefore 
required to prevent VH onset and often significant results are 
obtained by decreasing the drug dosage. If that maneuver does 
not reach the goal, the use of AA may help (Eng and Welty, 
2010; Desmarais et al., 2016).
The modulation of glutamatergic or opioid neurotransmitters 
is also involved in VH (Niesters et al., 2012; Sivanesan et al., 2016) 
but the exact activity of these systems is still largely unexplored. 
In summary, the neuropharmacology of VH is a fascinating and 
still "under construction" chapter of clinical neuroscience. The 
field is in need of additional functional and structural studies to 
shed light on a phenomenon that represents a clinical challenge 
and often an unmet therapeutic need.
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[¹¹C] DASB [¹¹C] 3-amino-4-(2-dimethylaminomethylphenylsulfanyl) 
-benzonitrile,
[¹²³I] FP-CIT [¹²³I] N-ω-fluoropropyl- 2β-carbomethoxy- 3β-(4-iodophenyl) 
nortropane
AA atypical antipsychotic







CNS central nervous system
COMT Catechol-O-methyl-transferase
DAN Dorsal Attention Network
DaT dopamine transporter
DLB Dementia with Lewy Bodies
DMT N, N-Dimethyltryptamine
DMN Default Mode Network
DOR δ opioid receptor
fMRI functional Magnetic Resonance Imaging
GABA gamma aminobutyric acid
KOR κ opioid receptor
LGN lateral geniculate nucleus
LSD lysergic acid diethylamide
LTP long-term potentiation
MAchR muscarinic receptor for acetylcholine
MAO-I Monoamine Oxidase Inhibitors
MAOI-B Inhibitor of monoamine oxidase B
MOR μ opioid receptor
mPFC medial prefrontal cortex
NAchR nicotinic receptor for acetylcholine
NaRI Noradrenaline Reuptake Inhibitors
NaSSA Noradrenergic and Specific Serotonergic Antidepressants
NMDA N-methyl-D-aspartate
OR opioid receptors
PCC posterior cingulate cortex
PCP Phencyclidine
PD Parkinson’s disease
PDD Parkinson’s Disease with Dementia




SNRI Serotonin-Norepinephrine Reuptake Inhibitors
SPECT Single Photon Emission Computed Tomography
SRI Serotonin Reuptake Inhibitor





VAN Ventral Attention Network
VH Visual Hallucinations
VPN Ventral posterior nucleus
VTA ventral tegmental area
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